Telix Pharmaceuticals has announced that Illuccix, its PSMA PET imaging agent for prostate cancer,
has received marketing authorization in Belgium. This approval supports Telix’s mission
to expand access to advanced imaging across Europe.
Health Technology Insights: CRESSO Names Kelly Crompvoets CMO and Interim ARCpoint Labs President
Illuccix helps detect prostate-specific membrane antigen (PSMA)–positive lesions
during initial staging or when recurrence or metastasis is suspected.
It enables accurate, earlier detection, allowing doctors to make
good-informed treatment decisions.
Health Technology Insights: Elekta, Gray Partner to Enhance Oncology Scheduling for ONE OIS
With this regulatory approval, many clinicians as well as patients in Belgium
can now access a proven diagnostic tool.Telix views this as an important step
in improving care for people living with prostate cancer.
The company is continuing to work with health systems and commercial partners
to bring Illuccix to other European markets and ensure smooth availability
of PSMA imaging solutions.
Health Technology Insights: QuidelOrtho Expands Leadership with Two Senior VP Appointments
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
